CAR T-Cell Therapy

Does CAR T-cell therapy work in solid tumours?

Not yet to the degree it works in blood cancers. The response rates that made CAR T-cell therapy standard in B-cell malignancies have not transferred to solid tumours, but the first solid-tumour trials are no longer showing nothing: a GUCY2C-targeted product reached a 40% response rate at its recommended dose in refractory colorectal cancer, against historical third-line benchmarks below 5%. Both settings are limited by antigen escape, and the solid-tumour toxicity profile is different rather than milder.

What the evidence shows

• In relapsed or refractory diffuse large B-cell lymphoma, an ultralow-dose CD19 CAR T-cell product engineered to co-express interleukin-10 produced an objective response in 92.3% of 13 patients, with complete remission in 84.6%. JAMA Oncology
• Durability is the constraint even in blood cancers: 7 of those 13 patients had relapsed or progressed by data cutoff, including two with CD19-negative relapse. JAMA Oncology
• In microsatellite-stable, third-line or later metastatic colorectal cancer, a GUCY2C-targeted CAR T-cell product achieved a 26.3% objective response rate across 19 evaluable patients, rising to 40.0% at the recommended phase II dose with a median progression-free survival of 7.0 months. Journal of Clinical Oncology
• That solid-tumour result is set against historical third-line benchmarks of 1.6% to 4.7%, a comparison with historical controls rather than a randomised arm. Journal of Clinical Oncology
• Toxicity tracks the target as much as the disease: on-target, off-tumour diarrhoea occurred in 70% of the colorectal patients and was grade 3 in 55%, a toxicity with no counterpart in the CD19 setting. Journal of Clinical Oncology
• Cytokine release syndrome affected 92.3% of patients in the lymphoma trial, weighted toward lower grades. JAMA Oncology
• Cytokine release syndrome affected 85% of patients in the colorectal trial, mostly grade 1-2, with all events resolving without glucocorticoids. Journal of Clinical Oncology
• Antigen escape recurs across both settings, and in colorectal cancer it is already driving development of dual- and multi-targeted constructs intended to address antigen-loss resistance. Journal of Clinical Oncology

What this evidence cannot settle

Both trials are single-centre phase 1 studies with no comparator arm and no randomisation, treating 13 and 20 patients respectively. Neither supports a direct efficacy comparison between the two settings, and neither establishes durability beyond a few months of follow-up. The 40% colorectal figure rests on the 10 patients treated at the recommended phase II dose.

This summary was assembled by an automated editorial process from the articles listed below. Every statement above links to the article that establishes it, and each of those articles is checked against its primary source before publication. No clinician has reviewed this page.